Status:
COMPLETED
Positron Emission Tomography (PET) Study
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
All Genders
20-45 years
Phase:
PHASE1
Brief Summary
The primary purpose is to study the occupancy at the α4β2 neuronal nicotinic receptor's (NNRs) and to determine the relation between plasma concentration of AZD1446 and the occupancy at α4β2 NNRs.
Eligibility Criteria
Inclusion
- Physically healthy volunteers
- Body weight between 50 to 100 kg and body mass index (BMI) between 19 and 30 kg/m2
Exclusion
- History of any clinically significant disease or disorder
- History of severe allergy/hypersensitivity reactions
- Participation in a PET examination as part of a scientific study during the past twelve months
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00886067
Start Date
April 1 2009
End Date
August 1 2009
Last Update
September 10 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Stockholm, Sweden